• OPEN AN ACCOUNT
Indian Indices
Nifty
22,419.95 -150.40
(-0.67%)
Sensex
73,730.16 -609.28
( -0.82%)
Bank Nifty
48,201.05 -293.90
( -0.61%)
Nifty IT
33,666.25 111.85
( 0.33%)
Global Indices
Nasdaq
15,927.90 316.14
(2.03%)
Dow Jones
38,239.66 153.86
(0.40%)
Hang Seng
17,651.15 366.61
(2.12%)
Nikkei 225
37,934.76 306.28
(0.81%)
Forex
USD-INR
83.31 0.00
(0.00%)
EUR-INR
89.11 0.15
(0.17%)
GBP-INR
103.70 0.42
(0.41%)
JPY-INR
0.54 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Vivimed Labs soars after Jeedimetla facility gets Ukraine GMP approval
04-Mar-21   14:00 Hrs IST
Vivimed Labs announced that its FDF manufacturing facility located in Jeedimetla, near Hyderabad inspected in August 2017 by the Ukraine Ministry of Health, has been approved and accredited with GMP Certification effective September 2017 and same has been renewed upto 4 February 2022 on 10 February 2021. The GMP approval extension also includes 5 new product registrations.

Ukraine is a member Country of PICS, whose members include many European Countries.

Ramesh Krishnamurthy, CEO of Vivimed Labs said: Successful renewal of PICS GMP Certification enables Vivimed to scale up its branded product distribution in CIS Countries. Export thrust is key contributor to the growth strategy of Vivimed.

Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.

On a consolidated basis, Vivimed Labs posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.

Powered by Capital Market - Live News